“Biosimilar products play a critical role in our corporate strategy,” Coherus BioSciences underlined as it revealed its latest filing plans for a pair of partnered biosimilar candidates: Bioeq’s FYB201 Lucentis (ranibizumab) and Innovent Biologics’ IBI305 Avastin (bevacizumab) products.
Bioeq is continuing to target mid-year 2021 for the submission of the ranibizumab biologics license application filing, while a COVID-induced delay to bevacizumab’s three-way pharmacokinetic study has pushed
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?